middle.news
Paradigm Biopharma Doses Patients in US and Australia, Eyes Mid-2026 Interim Analysis
11:02am on Tuesday 30th of September, 2025 AEST
•
Healthcare
Read Story
Paradigm Biopharma Doses Patients in US and Australia, Eyes Mid-2026 Interim Analysis
11:02am on Tuesday 30th of September, 2025 AEST
Key Points
Participants dosed in PARA_OA_012 Phase 3 trial in US and Australia
Site activations and MRI certifications nearing completion by October
Improved screen-failure rate following FDA-guided eligibility refinements
Recruitment initiatives underway including Hope4OA, Citeline, and Medimark
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Paradigm Biopharmaceuticals (ASX:PAR)
OPEN ARTICLE